Sumiaki Okamoto

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

Michael R. McClung, Michelle L. O’Donoghue, Socrates E. Papapoulos et al. · The Lancet Diabetes & Endocrinology · 2019 · 169 citations

Pharmacy, Pharmacotherapy, Bone Metabolism +10

A New Active Vitamin D, ED-71, Increases Bone Mass in Osteoporotic Patients under Vitamin D Supplementation: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial

Toshio Matsumoto, Takami Miki, Hiroshi Hagino et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 139 citations · Full text

Medicine, Nutritional Sciences, Pharmacotherapy +17

Inhibitory Effect of Interferon-<i>γ</i>on the Response of Human Thyrocytes to Thyrotropin (TSH) Stimulation: Relationship Between the Response to TSH and the Expression of DR Antigen

Yuji Nagayama, Motomori Izumi, Kiyoto Ashizawa et al. · The Journal of Clinical Endocrinology & Metabolism · 1987 · 67 citations

Life Sciences, Endocrinology, Immunology +6

Treatment of Graves' ophthalmopathy with high-dose intravenous methylprednisolone pulse therapy

Yuji Nagayama, Motomori Izumi, Takeshi Kiriyama et al. · European Journal of Endocrinology · 1987 · 55 citations

Medicine, Ophthalmology, Pharmacotherapy +12

24,24-Difluoro-25-hydroxyvitamin D3-enhanced bone mineralization in rats comparison with 25-hydroxyvitamin3 and vitamin D3

Sumiaki Okamoto, Yôko Tanaka, Hector F. De Luca et al. · Archives of Biochemistry and Biophysics · 1981 · 28 citations

Medicine, Endocrinology, Nutritional Sciences +14